NCT04265963 2023-04-18
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
Clinical Trials
33 trialsNCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04272125 2023-04-18
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04100187 2022-12-01
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Kecellitics Biotech Company Ltd
Phase 1 Unknown
NCT05291390 2022-11-29
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Armaceutica, Inc.
Phase 2 Unknown
NCT05227898 2022-10-25
RESTORE
Blue Note Therapeutics
Phase NA Unknown
NCT05480501 2022-07-29
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05212584 2022-07-06
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Phase 1 Unknown
NCT05445765 2022-07-06
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Phase 1 Unknown
NCT04632316 2022-06-21
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Glycostem Therapeutics BV
Phase 1/2 Unknown
NCT04709458 2022-05-03
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Taiga Biotechnologies, Inc.
Phase 1 Unknown
NCT05309213 2022-04-04
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT05061147 2021-10-01
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Maxinovel Pty., Ltd.
Phase 1/2 Unknown
NCT03798509 2021-08-31
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Hrain Biotechnology Co., Ltd.
Phase 1 Unknown
NCT02546739 2021-01-26
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Phase 1 Unknown
NCT03271515 2021-01-20
Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Phase 1 Unknown
NCT04439721 2021-01-06
γδT
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04336501 2020-12-17
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase NA Unknown
NCT04610125 2020-10-30
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT04497701 2020-08-04
Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase NA Unknown
NCT02735291 2020-07-15
EECNTL
Sinobioway Cell Therapy Co., Ltd.
Phase NA Unknown
NCT04163575 2019-12-23
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Kecellitics Biotech Company Ltd
Phase 1/2 Unknown
NCT03910842 2019-09-06
Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT03312205 2019-01-09
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Unknown
NCT03142646 2018-05-01
IM19CAR-T
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT02656147 2017-09-05
Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Phase 1 Unknown
NCT03121625 2017-04-25
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1 Unknown
NCT02672501 2016-02-03
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Shanghai GeneChem Co., Ltd.
Phase 1/2 Unknown
NCT01280786 2014-02-03
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Synta Pharmaceuticals Corp.
Phase 1 Unknown
NCT01983761 2013-11-18
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Phase 1/2 Unknown
NCT01657955 2012-08-06
CLL
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT00715637 2010-10-13
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
Antisoma Research
Phase 3 Unknown